Adenoid hypertrophy
Conditions
Interventions
study group:Administration of the anti-allergy drug montelukast sodium
control :Placebo control
Sponsors
Dalian municipal Central Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 8 Years
Inclusion criteria
Inclusion criteria: (1) Age 3-8 years ;(2) Nasal endoscopy and nasopharyngeal CT examination were performed in the Department of Otolaryngology, Head and Neck Surgery, Affiliated Central Hospital of Dalian University of Technology. Hypertrophic adenoids blocked more than 50% of the posterior nostrils or nasopharyngeal A/n ratio was 50% or more; (3) Surgical treatment is planned after 1 month; (4) The patient and his family had no history of montelukast allergy; (5) No surgical contraindications, the family members of the child signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Children with adenoidal hypertrophy combined with tonsillar hypertrophy or who have undergone tonsillectomy; (2) Children with comorbidities, such as secretory otitis media, chronic sinusitis, etc; (3) Children with craniofacial deformities, such as cleft palate and choanal atresia; (4) Current or previous use of montelukast sodium, acute upper respiratory tract infection, use of any corticosteroids, or use of antibiotics within 4 weeks prior to the study; (5)Severe cardiopulmonary dysfunction; (6) With severe infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological changes in adenoid tissue on light microscopy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood cell analysis; | — |
Countries
China
Contacts
Public Contactliudelong
Dalian municipal Central Hospital
Outcome results
None listed